Templin Barry L sold $8K of PRCT

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

BERKSHIRE HATHAWAY INC purchased 1,679,700 indirectly-held shares of LENNAR CORP /NEW/ (LEN) at an average of $81.19 ($79.42–$81.65, $136.38M total) across 9 trades over 2026-09-23 to 2026-09-25. Filed jointly with BUFFETT WARREN E (10% owner).

Zambrano Lozano Rogelio purchased 400,800 indirectly-held shares of CEMEX SAB DE CV (CX) at $17.28 ($6.93M total) on 2026-09-25.

Troendle August J. (President & CEO) sold 43,916 shares of Medpace Holdings, Inc. (MEDP) at an average of $624.01 ($621.33–$628.64, $27.40M total) across 2 trades over 2026-09-23 to 2026-09-24.